The Covid-19 pandemic catalysed the digital health revolution, including remote patient monitoring and mobile health.

America's automotive production and inventory, and ultimately sales, all took a massive hit and have not fully recovered. It ...

As the world awaits US tariff plans, countries are rearranging trade relationships according to geopolitical alliances.

Following today’s release of Tesco’s figures for the 19 weeks ending 4 January 2025; Sofie Willmott, Associate Retail Director at GlobalData, a leading data ...

One driver is the introduction of drugs targeting unmet needs. The heart failure (HF) sector across the seven major markets is projected to reach $33.7b by 2032 at a compound annual growth rate of 9.6 ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to watch in 2025.

Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease (TED).

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Data from the largest US Lyme disease registry suggests that 90% of PLD patients are excluded from clinical trials.

Novartis has announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) achieved the primary ...